Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for finerenone (Kerendia), a non‑steroidal mineralocorticoid receptor antagonist (MRA), supporting a potential new indication in adults with chronic kidney disease (CKD) without diabetes – a population that currently lacks approved disease‑modifying therapies.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Application Type | Supplemental New Drug Application (sNDA) |
| Product | Finerenone (Kerendia / Firialta) |
| Proposed Indication | Treatment of adults with CKD without diabetes |
| Pivotal Trial | FIND‑CKD (Phase III) |
| Acceptance Date | 8 Oct 2026 |
| Current Approvals | CKD associated with T2D (>100 countries); HF with LVEF ≥ 40% (US, EU, Japan, China, others) |
Drug Profile & Mechanism of Action
- Molecule: Finerenone – a selective, non‑steroidal mineralocorticoid receptor antagonist (MRA) with a distinct binding profile compared to steroidal MRAs (spironolactone, eplerenone)
- Mechanism: Blocks overactivation of the mineralocorticoid receptor, reducing inflammation, fibrosis, and maladaptive cardiac and renal remodeling – key drivers of CKD progression irrespective of diabetic etiology
- Differentiation: Unlike steroidal MRAs, finerenone demonstrates potent anti‑inflammatory and anti‑fibrotic effects with a lower risk of hyperkalemia, enabling broader use in CKD populations
- Brand Names: Kerendia (global); Firialta (selected markets)
- Development Stage: Marketed since 2021; sNDA represents a label‑expansion into non‑diabetic CKD
Clinical Evidence – Phase III FIND‑CKD Study
| Endpoint | Result | Comparator |
|---|---|---|
| Kidney Disease Progression | Significantly delayed vs. placebo | Placebo + standard of care |
| Cardiovascular‑Kidney Events | Significantly reduced vs. placebo | Placebo + standard of care |
| Population | Broad population of adults with CKD without diabetes | – |
| Design | Randomized, double‑blind, placebo‑controlled, added to standard of care | – |
| Specific Efficacy Endpoints | Hazard ratios and absolute risk reductions Not disclosed in press release | – |
The FIND‑CKD trial enrolled a broad spectrum of non‑diabetic CKD patients and demonstrated that finerenone, when added to standard of care (including RAS blockade where appropriate), delivered statistically significant benefits in both renal and cardiovascular‑kidney composite endpoints. This positions finerenone as the first MRA to demonstrate such a dual benefit in a non‑diabetic CKD population.
Market Impact & Outlook
- Non‑Diabetic CKD Landscape: CKD affects an estimated 800+ million people globally, with the non‑diabetic subset representing the majority of CKD patients. No therapy is currently FDA‑approved specifically for disease modification in this population, representing a substantial unmet need.
- Label Expansion Significance: A successful sNDA would transform finerenone from a diabetes‑adjacent CKD drug into a broad‑spectrum renal‑protective agent, dramatically expanding the addressable patient population and commercial opportunity.
- Revenue Trajectory: Kerendia/Firialta is already commercialized in >100 countries for diabetic CKD; adding the non‑diabetic indication could meaningfully accelerate sales growth. Specific revenue projections Not disclosed.
- Competitive Positioning: Finerenone’s established safety profile in >100 markets and its dual cardiorenal benefit differentiate it from SGLT2 inhibitors and endothelin receptor antagonists that are also being evaluated in CKD.
- Cardiovascular Franchise Synergy: Finerenone’s existing heart failure approval (LVEF ≥ 40%) in the US, EU, Japan, and China creates a cross‑indication commercial platform spanning nephrology and cardiology prescribers.
- Regulatory Timeline: FDA acceptance of the sNDA initiates the review clock; a PDUFA target action date has not been disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review, clinical outcomes, and commercial potential of finerenone in non‑diabetic CKD. FDA acceptance of an sNDA does not constitute approval. Actual results may differ due to risks including the outcome of regulatory review, post‑marketing requirements, competitive dynamics, and reimbursement decisions.-Fineline Info & Tech
